Vernalis PLC Block listing Interim Review (2209L)

TIDMVER

RNS Number : 2209L

Vernalis PLC

29 September 2016

BLOCK LISTING SIX MONTHLY RETURN

VERNALIS PLC (the "Company")

29 September 2016

Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 
 Name of applicant:                   Vernalis plc 
-----------------------------------  --------------------------------------------------- 
 Name of scheme(s):                   2007 Long Term Incentive Scheme 
                                       ("LTIP") and the Savings Related 
                                       Share Option Plan 2003 ("SAYE") 
-----------------------------------  --------------------------------------------------- 
 Period of return (from               From: 29/Mar/2016           To: 29/Sept/2016 
  / to): 
-----------------------------------  --------------------------  ----------------------- 
 Balance of unallotted securities     Total of 2,243,318 Ordinary 1p 
  under scheme(s) from previous        Shares, split: 
  return:                               *    Under LTIP = 2,243,318 Ordinary 1p Shares 
 
 
                                        *    Under SAYE = NIL Ordinary 1p Shares 
-----------------------------------  --------------------------------------------------- 
 Plus: The amount by which            NIL 
  the block scheme(s) has 
  been increased or application 
  has been made to increase 
  since the date of the last 
  return (if any increase 
  has been applied for): 
-----------------------------------  --------------------------------------------------- 
 Less: Number of securities           Total of 1,074,958 Ordinary 1p 
  issued/allotted under scheme(s)      Shares, split: 
  during period:                        *    Under LTIP = 1,074,958 Ordinary 1p Shares 
 
 
                                        *    Under SAYE = NIL Ordinary 1p Shares 
-----------------------------------  --------------------------------------------------- 
 Less: Number of securities 
  forfeited under scheme(s) 
  during period:                      767,304 
-----------------------------------  --------------------------------------------------- 
 Equals: Balance under scheme(s)      Total of 401,056 Ordinary 1p Shares, 
  not yet issued/allotted              split: 
  at end of period:                     *    Under LTIP = 401,056 Ordinary 1p Shares 
 
 
                                        *    Under SAYE = NIL Ordinary 1p Shares 
-----------------------------------  --------------------------------------------------- 
 Number and class of securities        No. of Ordinary   Date on which Shares 
  originally admitted and                1p Shares         were Admitted to 
  the date of admission (including                         Trading 
  any additions):                      ----------------  --------------------- 
                                        350,000           6 November 2013, 
                                                           plus 
                                       ----------------  --------------------- 
                                        1,049,317         12 May 2014, plus 
                                       ----------------  --------------------- 
                                        1,058,184         12 May 2015, plus 
                                       ----------------  --------------------- 
                                        1,638,364         30 September 2015 
                                       ----------------  --------------------- 
                                        1,189,296         1 April 2016 
                                       ----------------  --------------------- 
-----------------------------------  --------------------------------------------------- 
 

-- ends -

Enquiries:

 
 Vernalis plc:                             [phone] 
 Ian Garland, Chief Executive Officer 
 David Mackney, Chief Financial Officer 
 Canaccord Genuity Limited (Nominated 
  Adviser):                                [phone] 
 Dr Julian Feneley 
 Henry Fitzgerald-O'Connor 
 Rupert Winckler 
 Emma Gabriel 
 Shore Capital (Joint Broker):             [phone] 
 Bidhi Bhoma 
 Toby Gibbs 
 FTI Consulting:                           [phone] 
 Ben Atwell 
 Simon Conway 
 Stephanie Cuthbert 
 

Notes to Editors

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra(R) XR targeting the US prescription cough cold market; MOXATAG(R) , a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and Tris.

For further information about Vernalis, please visit www.vernalis.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

BLRLLMMTMBATBBF

(END) Dow Jones Newswires

September 29, 2016 10:00 ET (14:00 GMT)